

UNCLASSIFIED

AD NUMBER
ADB287328
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Sep 2002. Other requests shall be referred to USAMRMC, Ft. Detrick, MD 21702
AUTHORITY
USAMRMC ltr, DTD 01 Jul 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-00-1-0632

TITLE: Mapping genetic modifiers of mammary tumor susceptibility
in BALB/c-Trp53+/-mice

PRINCIPAL INVESTIGATOR: D. Joseph Jerry, Ph.D.

CONTRACTING ORGANIZATION: University of Massachusetts
Amherst, Massachusetts 01003

REPORT DATE: September 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Sep 02). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20030319 054

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-00-1-0632
Organization: University of Massachusetts

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

1/24/03

Kath Mm 2/13/03

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE September 2002	3. REPORT TYPE AND DATES COVERED Final (1 September 2000 - 31 August 2002)
----------------------------------	----------------------------------	---

4. TITLE AND SUBTITLE Mapping genetic modifiers of mammary tumor susceptibility in BALB/c-Trp53+/-mice	5. FUNDING NUMBER DAMD17-00-1-0632
---	---------------------------------------

6. AUTHOR(S) D. Joseph Jerry, Ph.D.
--

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Massachusetts Amherst, Massachusetts 01003 email - jjerry@vasci.umass.edu	8. PERFORMING ORGANIZATION REPORT NUMBER
---	---

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSORING / MONITORING AGENCY REPORT NUMBER
---	---

11. SUPPLEMENTARY NOTES Original contains color plates: All DTIC reproductions will be in black and white.

12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Sep 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.	12b. DISTRIBUTION CODE
---	------------------------

13. ABSTRACT (Maximum 200 Words) The TP53 tumor suppressor gene is defective in the majority of sporadic breast cancers. Breast cancer is also the most frequent tumor type in women with Li-Fraumeni syndrome who inherit germline mutations in TP53. This suggests that p53 is fundamental to the growth regulation and prevention of tumors in the mammary epithelium. However, the incidence of mammary tumors in p53-deficient mice varies greatly among strains. We have undertaken the genetic mapping of modifiers of susceptibility by performing genetic crosses between mammary tumor-susceptible BALB/c-Trp53+/- mice and -resistant C57BL/6-Trp53+/- mice. Mammary tumor susceptibility was shown to segregate as a partially dominant trait with recessive-acting modifiers also detected. BALB/c alleles of the Cdkn2a and Prkdc genes had been shown to confer tumor susceptibility previously, and therefore examined for association with the mammary tumor susceptibility phenotype. Neither gene segregated as a major modifier, however, Cdkn2a was shown to alter latency of lymphomas. Therefore, a genome pan was undertaken. The results indicate the presence of a major modifier gene on mouse chromosome 7. The interval is being narrowed with additional markers and candidate genes will be analyzed for polymorphisms.

14. SUBJECT TERMS genetic mapping, p53, susceptibility, breast cancer	15. NUMBER OF PAGES 8
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT Unclassified Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited
---	--	--	---

Table of Contents

Cover.....	
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	4
Reportable Outcomes.....	5
Conclusions.....	5
References.....	6
Appendices.....	7

Introduction:

The *TP53* tumor suppressor gene is critical for inhibiting tumor development in many tissues. In the breast epithelium this is evident from the high incidence of breast cancers in Li-Fraumeni syndrome (LFS) patients who inherit germline mutations in *TP53* (Kleihues et al., 1997). However, the incidence and age of onset of breast cancer in LFS patients bearing identical mutations varies dramatically. Genes that segregate independently of *TP53* may interact with p53 status to modify tumor susceptibility in LFS patients and in the general population. These modifier alleles may carry a very small risk of breast cancer when considered alone (*i.e.* low-penetrance alleles), but can have dramatic effects when combined with other susceptibility alleles. Low-penetrance alleles would have little selective disadvantage by themselves, and therefore, may represent relatively common alleles in the general population. Therefore, genetic susceptibility may belie a much larger proportion of breast cancer due to the presence of low-penetrance (Ponder, 2001). Though low-penetrance modifier loci may represent important contributors of overall risk as well as targets of therapy, their subtle effects would be indistinguishable from "sporadic" breast cancer due to the complex patterns of inheritance in human populations.

While mammary tumors are observed infrequently in C57BL/6-*Trp53*^{+/-} mice {DNEHOWER1995A}{Donehower et al., 1995}, we demonstrated a high incidence of spontaneous mammary tumors in BALB/c-*Trp53*^{+/-} females (Kuperwasser et al., 2000). In this project we exploited this difference in mammary tumor susceptibility among strains to determine the pattern of inheritance of mammary tumor susceptibility and genetically map chromosomal intervals harboring genes that alter susceptibility to mammary tumors.

Body:

The initial work of mating mice to prepare female (C57BL/6xBALB/cMed)F1 progeny and backcross to BALB/c-*Trp53*^{-/-} males to prepare the mapping panel of female mice heterozygous for *Trp53* has been completed (Appendix 1A). A total of 220 females have been monitored for tumor incidence for >15 months. Homozygosity for the candidate genes *Cdkn2a* and *Prkdc*, for which it was known the BALB/c strain harbors variants that reduce protein function, has been analyzed for segregation with the mammary tumor phenotype. A genome-wide pan for linkage of susceptibility loci to markers has been completed (Appendix 2).

Key Research Accomplishments:

- The mapping panel of mice has been generated providing a tool to examine a wide spectrum of candidate genes.
- Interactions between BALB/c and C57BL/6J alleles of *Prkdc* and *Cdkn2a* were detected and shown to differentially affect the probability of developing lymphoma and osteosarcomas.
- Mammary tumor susceptibility was not linked to either *Prkdc* or *Cdkn2a*.
- The genome scan identified linkage of a single major modifier locus on the distal

- end of mouse chromosome 7.
- Transcriptional profiling has identified 4 genes within the interval that are differentially expressed.

Reportable outcomes:

- Data presented at the Gordon Research Conference in Mammary Gland Biology (June 2001).
- Data presented at the Era of Hope meeting (Sept. 2002)
- A repository of >80 matched normal and tumor mammary tissue and DNA has been established. Tissues are available for genetic and histologic analyses.
- Two manuscripts are in preparation based on these results. The first describes the patterns of inheritance and interactions between the alleles of the *Cdkn2a* and *Prkdc* loci in different tumor types (lymphoma, osteosarcoma and mammary carcinoma). The second manuscript describes the mechanism by which the wild type allele of *Trp53* is lost in mammary tumors.
- One M.S. graduate student (Christine McLary), 3 undergraduates (Tamar Soffer, Jennifer Brown and Jordyn Boesch) and one post-doctoral fellow (Dr. Anneke Blackburn) were trained during the course of this project. Christy McLary has taken a technical position at the Dana-Farber Cancer Center, Boston, MA. Tamar Soffer is working in a forensics lab in New York City. Jennifer Brown accepted a technical position at U. Mass. Medical School in Worcester. Dr. Blackburn has gained valuable experience with mammary gland and tumor biology in preparation for an independent career. She was awarded a post-doctoral fellowship for her work and has returned to the John Curtin Medical Research Center at the Australian National University in Canberra.



Conclusions:

- Susceptibility to mammary tumors resulted from a combination of dominant-acting modifiers as well as recessive-acting modifiers.
- Loss of heterozygosity of p53 is an obligate part of the process and proceeds via a homologous recombination mechanism.
- The the BALB/c and C57BL/6 alleles of the candidate genes tested (*Cdkn2a*, *Prkdc*) had significant effects on the probability of lymphomas and osteosarcomas, but did not affect mammary tumors.
- Preliminary efforts suggest linkage of the recessive-acting modifiers to mouse chromosome 7.

References:

1. Donehower, L.A., Harvey, M., Vogel, H., McArthur, M.J., Montgomery, C.A., Park, S.J., Thompson, T., Ford, R.J., and Bradley, A. (1995). Effects of genetic background on tumorigenesis in p53-deficient mice. *Mol. Carcinogenesis* 14, 16-22.
2. Kleihues, P., Schauble, B., zur, H.A., Esteve, J., and Ohgaki, H. (1997). Tumors associated with p53 germline mutations: a synopsis of 91 families. *Am. J. Pathol.* 150, 1-13.
3. Kuperwasser, C., Hurlbut, G.D., Kittrell, F.S., Dickinson, E.S., Laucirica, R., Medina, D., Naber, S.P., and Jerry, D.J. (2000). Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice : A model for Li-fraumeni syndrome. *Am. J. Pathol.* 157, 2151-2159.
4. Ponder, B.A. (2001). Cancer genetics. *Nature* 411, 336-341.

Appendices:





DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MD 21702-5012

REPLY TO
ATTENTION OF

MCMR-RMI-S (70-1y)

1 July 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB274518
ADB287328
ADB277943
ADB288221
ADB248332
ADB265760
ADB287619
ADB281577
ADB287600
ADB288422
ADB288375
ADB268297